Additional partnership in medical technology: Bosch and R-Biopharm to strengthen Vivalytic analysis platform Plans to use innovative Bosch BioMEMS technology in PCR tests for multiresistant bacteria
- Bosch and R-Biopharm are jointly investing 150 million euros in the development of new PCR tests and in marketing.
- PCR test for multiresistant gram-negative (MRGN) bacteria to be developed using novel BioMEMS technology.
- BioMEMS chips permit simultaneous testing of up to 250 genetic characteristics – in some cases, in less than 15 minutes.
Darmstadt, Gerlingen, and Waiblingen, Germany – The market for medical technology is innovative, dynamic, and growing. Bosch sees medical technology as a strategic growth field and intends to expand its Bosch Healthcare Solutions subsidiary, based in Waiblingen. Bosch has now entered into a new partnership with the German diagnostics solutions company R-Biopharm. This partnership will be focused on Bosch’s universal, fully automated Vivalytic molecular diagnostic analysis platform. The two companies will invest a total of 150 million euros by the end of the decade. Within their strategic development and distribution partnership, the partners intend to develop new in vitro diagnostic tests for the Vivalytic platform – including a PCR test for multiresistant bacteria based on the innovative Bosch BioMEMS technology. They are also looking to strengthen their marketing operations.
“We are expanding in medical technology, a market we have defined as a strategic growth field. The fact that we can apply our many years of expertise and experience in the research and development of microchips, molecular diagnostics, and miniaturization, as well as our manufacturing know-how, makes this an attractive prospect for us,” says Stefan Hartung, chairman of the Bosch board of management. “In medical technology, partnership models are a useful way of shortening product cycles and opening up distribution channels in this dynamic, innovative market,” he adds. Point-of-care molecular diagnostics is expected to become a market worth billions. Bosch Healthcare Solutions and
R-Biopharm aim to achieve sales in the medium nine-figure range by 2030.
The R-Biopharm Group, based in Darmstadt, Germany, has many years of expertise in clinical and food diagnostics. In addition, the company has well-established sales channels worldwide and knowledge of the relevant markets. “Our partnership with Bosch Healthcare Solutions marks a significant milestone in the implementation of the R-Biopharm Group’s growth strategy in the field of clinical diagnostics,” says Dr. Frank Apostel, Chief Operating Officer Clinical Diagnostics and Nutrition Care at R-Biopharm. “Together, we will work toward the goal of offering excellent products and solutions that can play a major part in combating diseases and developing medicines,” he adds.
Partnership goals: develop new PCR tests and strengthen sales
One development goal within the ten-year partnership is a test for multiresistant gram-negative (MRGN) bacteria, which is to be implemented using Bosch’s innovative, novel BioMEMS technology. The healthcare system faces the challenge of coping with an increasing number of diseases caused by multiresistant bacteria: in 2019, antimicrobial resistance had a hand in 4.95 million deaths worldwide, and each year, 670,000 infections caused by antibiotic-resistant bacteria occur in Europe. In recent years, these bacteria have become a problem in hospitals – which administer particularly large quantities of antibiotics in the course of treating patients. In addition to the health risks, the financial burden of hygiene and quarantine measures in the healthcare sector should not be underestimated.
Vivalytic: even faster and more efficient with Bosch BioMEMS technology
As compact as a desktop computer tower, the universal, fully automatic Vivalytic Analyser is a platform for which various manufacturers can quickly and easily adapt and implement tests. The test cartridges already contain all the necessary reagents. “You could say we’ve shrunk a laboratory down to the size of a smartphone,” says Marc Meier, president of Bosch Healthcare Solutions. “BioMEMS technology makes our Vivalytic platform even faster and more efficient, since this high-performance silicon chip, developed and manufactured by Bosch, enables fully automatic, simultaneous testing of up to 250 genetic characteristics such as pathogens in a single test cartridge, in some cases in less than 15 minutes,” he adds. “This marks the entry of Bosch and its partners into nanofluidics, which processes very small quantities of liquids in the nanoliter range.” This further miniaturization underscores the advantages of the Vivalytic platform: its compact size enables fast and targeted diagnostics directly at the point of sample collection – either at the doctor’s office or in the hospital – without the frequently time-consuming detour via a central laboratory. Medically trained specialists can carry out the PCR tests without special laboratory training.
The two companies want to develop further PCR tests to detect tuberculosis and determine any drug resistance. A few days ago, Bosch announced its first partnership with the Northern Irish medical technology company Randox Laboratories Ltd. By the end of the decade, Bosch and its two partners will have invested some 300 million euros in the further development of the Vivalytic analysis platform.
Press photos and infographics are available on the Bosch Media Service at
www.bosch-press.com
Bosch contact:
Dörthe Warnk
Phone: +49 711 811-55508
E-mail: doerthe.warnk@bosch.com
R-Biopharm contact:
Yvonne Kress
Phone: +49 6151 8102-4319
E-mail: Y.Kress@r-biopharm.de
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Democracy News Alliance: Report: BRICS+ likely new counterpoint to G7-led geopolitical order2.5.2024 10:08:19 CEST | Press release
Los Angeles/DNA - The expansion of the BRICS group of nations into what has informally been named BRICS+ could highlight a geopolitical shift, with the new grouping positioning itself as a counterpoint to the Western-led geopolitical order, a report published by the Luskin School of Public Affairs at the University of California Los Angeles (UCLA) argues.
Democracy News Alliance: Sahel elites must move away from 'zero-sum' policies, report urges2.5.2024 09:48:23 CEST | Press release
Los Angeles/DNA - A dual economic strategy focusing on domestic economic development and international partnerships to address the underlying challenges facing the Sahel region could help Burkina Faso, Mali, Niger and Sudan to build more resilient institutions and foster long-term development, a recently published report says.
Dwinity IP GmbH: Nillion is pleased to announce that Dwinity, a team pioneering decentralized AI has joined as an ecosystem partner2.5.2024 09:38:30 CEST | Press release
With huge amounts of personal data being collected every day, privacy concerns are escalating as the impact of data breaches become more costly. The need to address the problems created by the existing data economy have never been greater. By empowering users to reclaim control, Dwinity aims to unlock an enormous amount of potential for personal data to enhance various industries like healthcare, insurance, and finance.
Nano-Care Deutschland AG launches next generation of sustainable PFAS-free oleophobic coatings29.4.2024 08:39:10 CEST | Press release
Nano-Care Deutschland AG, leader in the development of innovative surface finishes, is excited to announce the launch of its latest product range. Taking “next generation products” as its theme, the company is introducing a range of revolutionary solutions that not only offer maximum performance, but also place a strong emphasis on sustainability and environmental compatibility.
New management for the EUTOP Group22.4.2024 10:51:42 CEST | Press release
Stefan Mappus is the new Managing Director of the EUTOP Group. Together with long-standing Managing Director Christian Schaufler, he will manage the fortunes of the Group from now on. Stefan Mappus is responsible for EUTOP's client business as a member of the management board and thus brings his wealth of experience in politics, administration and business directly to the benefit of EUTOP's clients.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom